Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05987644 2026-04-08

DURABLE

Phase 1/2 Recruiting

56 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02314481 2025-05-23

DARWINII

Phase 2 Active not recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06709274 2024-11-29

MOTION-NSCLC

Phase NA Not yet recruiting

342 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

Phase 2 Active not recruiting

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06339554 2024-04-01

TOSS-ALK

Completed

98 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

154 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1/2 Terminated

5 enrolled 8 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT04708639 2021-02-02

MonAlec

Unknown

40 enrolled

Thoracic

Lung Neoplasms, Disease Resistance

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Alectinib Pharmacokinetic in Patients With NSCLC

DURABLE

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

DARWINII

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

MOTION-NSCLC

PIKACHU

ATPase

ALNEO

EROS

ADAPT ALEC

TOSS-ALK

BLISS

ROME

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

MonAlec

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study